Solution-mediated phase transformation: Significance during dissolution and implications for bioavailability

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 2996-3018

  Greco, Kristyn ^a   Bogner, Robin ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Amorphous; Bioavailability; Biopharmaceutics Classification System (BCS); Cocrystals; Crystallization; Dissolution; Polymorph; Solubility

Indexed keywords

CARBAMAZEPINE; CHLORAMPHENICOL PALMITATE; LAMOTRIGINE; LONIDAMINE; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; SODIUM CHLORIDE;

AREA UNDER THE CURVE; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FLOW; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PHASE TRANSITION; REVIEW; SOLUTION MEDIATED PHASE TRANSFORMATION; X RAY POWDER DIFFRACTION;

EID: 84864038458     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23025     Document Type: Review

References (128)

1. Lipinski CA. 2001. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44(1):235-249.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
3. Bahl D, Bogner RH. 2006. Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res 23(10):2317-2325.
4. Good DJ, Rodriguez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Crystal Growth Des 9(5):2252-2264.
5. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397-404.
6. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86(1):1-12.
7. Horter D, Dressman JB. 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 46(1-3):75-87.
8. Kato Y, Kohketsu M. 1981. Relationship between polymorphism and bioavailability of drug. Part II. Relationship between polymorphism and bioavailability of amobarbital in the rabbit. Chem Pharm Bull 29(1):268-272.
9. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design, and performance. Critical Rev Ther Drug Carrier Syst 21(3):133-193.
10. Li S, Wong S, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. 2005. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res 22(4):628-635.
11. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 99(3):1254-1264.
12. Pudipeddi M, Serajuddin Abu TM. 2005. Trends in solubility of polymorphs. J Pharm Sci 94(5):929-939.
13. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59(7):603-616.
14. Stahl PH, Wermuth CG, Eds. 2002. Handbook of pharmaceutical salts: Properties selection and use. Wiley-VCH, Germany pp 9-115.
15. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93(3):563-570.
16. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98(8):2549-2572.
17. Cardew PT, Davey RJ. 1985. The kinetics of solvent-mediated phase transformations. Proc R Soc Lond A Math Phys Eng Sci 398(1815):415-428.
18. Aaltonen J, Heinanen P, Peltonen L, Korteiarvi H, Tanninen VP, Christiansen L, Hirvonen J, Yliruusi J, Rantanen J. 2006. In situ measurement of solvent-mediated phase transformations during dissolution testing. J Pharm Sci 95(12):2730-2737.
19. Chen Linna R, Wesley James A, Bhattachar S, Ruiz B, Bahash K, Babu Suresh R. 2003. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm Res 20(5):797-801.
20. Greco K, Bogner R. 2010. Crystallization of amorphous indomethacin during dissolution: Effect of processing and annealing. Mol Pharm 7(5):1406-1418.
21. Li S, Doyle P, Metz S, Royce AE, Serajuddin ATM. 2005. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J Pharm Sci 94(10):2224-2231.
22. Greco K, McNamara DP, Bogner R. 2011. Solution-mediated phase transformation of salts during dissolution: Investigation using haloperidol as a model drug. J Pharm Sci 100(7):2755-2768.
23. Mullin JW. 2001. Crystallization. 4th ed. Oxford: Butterworth-Heinemann, pp 181-285.
24. Rodriguez-Hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88(7):651-660.
25. Myerson, A. 2004. Handbook of industrial crystallization; 2nd ed., Butterworth-Heinemann, Woburn, MA pp 33-97.
26. Gu C-H, Young V Jr., Grant DJW. 2001. Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci 90(11):1878-1890.
27. Maruyama S, Ooshima H, Kato J. 1999. Crystal structures and solvent-mediated transformation of Taltirelin polymorphs. Chem Eng J (Lausanne) 75(3):193-200.
28. Wang F, Wachter JA, Antosz FJ, Berglund KA. 2000. An investigation of solvent-mediated polymorphic transformation of progesterone using in situ Raman spectroscopy. Org Process Res Dev 4(5):391-395.
29. Dressman J, Kraemer J, Eds. 2005. Pharmaceutical dissolution testing. Taylor & Francis group, Boca Raton, FL. pp 97-246.
30. USP. 2009. The United States pharmacopeia. 32 ed. Rockville: United States Pharmacopeial Convention, Inc.
31. Gao Z. 2011. Mathematical modeling of variables involved in dissolution testing. J Pharm Sci 100(11):4934-4942.
32. Siepmann J, Peppas NA. 2001. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 48(2-3):139-157.
33. Baxter JL, Kukura J, Muzzio FJ. 2005. Hydrodynamics-induced variability in the USP apparatus II dissolution test. Int J Pharm 292(1-2):17-28.
34. Kukura J, Baxter JL, Muzzio FJ. 2004. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions. Int J Pharm 279(1-2):9-17.
35. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2011. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement. Pharm Dev Technol 16(3):187-200.
36. Alonzo DE, Zhang GGZ, Zhou D, Gao Y, Taylor LS. 2010. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 27:608-618.
37. Levich VG. 1962. Physicochemical hydrodynamics. Upper Saddle River, New Jersey: Prentice Hall, pp 60-78.
38. Greco K, Bergman Theodore L, Bogner R. 2011. Design and characterization of a laminar flow-through dissolution apparatus: Comparison of hydrodynamic conditions to those of common dissolution techniques. Pharm Dev Technol 16(1):75-87.
39. Avdeef A, Tsinman O. 2008. Miniaturized rotating disk intrinsic dissolution rate measurement: Effects of buffer capacity in comparisons to traditional Wood's apparatus. Pharm Res 25(11):2613-2627.
40. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 23(8):1888-1897.
41. Bogner RH, Bergman TL, Greco K, Michaels DJ, Chawarski SJ. 2008. Flow-through apparatus for microscopic investigation of dissolution of pharmaceutical solids. US patent number 7892492 pp 34.
42. Shah AC, Nelson KG. 1975. Evaluation of a convective diffusion drug dissolution rate model. J Pharm Sci 64(9):1518-1520.
43. Southard MZ, Green DW, Stella VJ, Himmelstein KJ. 1992. Dissolution of ionizable drugs into unbuffered solution: A comprehensive model for mass transport and reaction in the rotating disk geometry. Pharm Res 9(1):58-69.
44. Sun W, Larive CK, Southard MZ. 2003. A mechanistic study of danazol dissolution in ionic surfactant solutions. J Pharm Sci 92(2):424-435.
45. Greco K, Bogner R. 2011. Solution-mediated phase transformation of haloperidol mesylate in the presence of sodium lauryl sulfate. AAPS Pharm Sci Tech 12(3):909-916.
46. Lehto P, Aaltonen J, Tenho M, Rantanen J, Hirvonen J, Tanninen VP, Peltonen L. 2009. Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J Pharm Sci 98(3):985-996.
47. van der Weerd J, Chan KLA, Kazarian SG. 2004. An innovative design of compaction cell for in situ FT-IR imaging of tablet dissolution. Vibrational Spectrosc 35(1-2):9-13.
48. van der Weerd J, Kazarian SG. 2004. Combined approach of FTIR imaging and conventional dissolution tests applied to drug release. J Control Release 98(2):295-305.
49. Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, Yliruusi J. 2009. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm 71(1):71-79.
50. van der Weerd J, Kazarian SG. 2005. Release of poorly soluble drugs from HPMC tablets studied by FTIR imaging and flow-through dissolution tests. J Pharm Sci 94(9):2096-2109.
51. Anquetil PA, Brenan CJH, Marcolli C, Hunter IW. 2003. Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes. J Pharm Sci 92(1):149-160.
52. Basavoju S, Bostroem D, Velaga SP. 2008. Indomethacin-saccharin cocrystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm Res 25(3):530-541.
53. Brittain HG. 2004. Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phase. J Pharm Sci 93(2):375-383.
54. Rodriguez-Hornedo N, Lechuga-Ballesteros D, Wu HJ. 1992. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int J Pharm 85(1-3):149-162.
55. Tian F, Zeitler JA, Strachan CJ, Saville DJ, Gordon KC, Rades T. 2006. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J Pharm Biomed Anal 40(2):271-280.
56. Caillet A, Puel F, Fevotte G. 2006. In-line monitoring of partial and overall solid concentration during solvent-mediated phase transition using Raman spectroscopy. Int J Pharm 307(2):201-208.
57. Young WWL, Suryanarayanan R. 1991. Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions. J Pharm Sci 80(5):496-500.
58. Debnath S, Predecki P, Suryanarayanan R. 2004. Use of glancing angle X-ray powder diffractometry to depth-profile phase transformations during dissolution of indomethacin and theophylline tablets. Pharm Res 21(1):149-159.
59. Imaizumi H, Nambu N, Nagai T. 1980. Stability and several physical properties of amorphous and crystalline form of indomethacin. Chem Pharm Bull (Tokyo) 28(9):2565-2569.
60. Chikaraishi Y, Otsuka M, Matsuda Y. 1996. Preparation of amorphous and polymorph piretanide and their physicochemical properties and solubilities. Chem Pharm Bull 44(8):1614-1617.
61. Chikaraishi Y, Otsuka M, Matsuda Y. 1996. Dissolution phenomenon of the piretanide amorphous form involving phase change. Chem Pharm Bull 44(11):2111-2115.
62. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21(10):1762-1769.
63. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim, Germany: Wiley-VCH, pp 167-184.
64. Garcia E, Hoff C, Veesler S. 2002. Dissolution and phase transition of pharmaceutical compounds. J Cryst Growth 237-239(Pt. 3):2233-2239.
65. Chawla G, Bansal AK. 2007. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci 32(1):45-57.
66. Paulekuhn GS, Dressman JB, Saal C. 2007. Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database. J Med Chem 50(26):6665-6672.
67. McNamara DP, Amidon GL. 1986. Dissolution of acidic and basic compounds from the rotating disk: Influence of convective diffusion and reaction. J Pharm Sci 75(9):858-868.
68. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. 1981. Dissolution kinetics of carboxylic acids. I: Effect of pH under unbuffered conditions. J Pharm Sci 70(1):13-22.
69. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. 1981. Dissolution kinetics of carboxylic acids. II: Effects of buffers. J Pharm Sci 70(1):22-32.
70. Higuchi WI, Parrott EL, Wurster DE, Higuchi T. 1958. Investigation of drug release from solids. II. Theoretical and experimental study of influences of bases and buffers on rates of dissolution of acidic solids. J Am Pharm Assoc 47:376-383.
71. Serajuddin AT, Jarowski CI. 1985. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. I: Phenazopyridine. J Pharm Sci 74(2):142-147.
72. Avdeef A, Tsinman O. 2008. Miniaturized rotating disk intrinsic dissolution rate measurement: Effects of buffer capacity in comparisons to traditional Wood's apparatus. Pharm Res 25(11):2613-2627.
73. Jain A, Ran Y, Yalkowsky Samuel H. 2004. Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): A technical note. AAPS PharmSciTech 5(3):e45.
74. Bernstein J, Davey RJ, Henck J-O. 1999. Concomitant polymorphs. Angew Chem Int Ed 38(23):3441-3461.
75. Brittain HG. 2009. Polymorphism in pharmaceutical solids. 2nd ed. New York: Informa Press, pp 481-509.
76. Barbas R, Marti F, Prohens R, Puigjaner C. 2006. Polymorphism of norfloxacin: Evidence of the enantiotropic relationship between polymorphs A and B. Crystal Growth Des 6(6):1463-1467.
77. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193(2):137-146.
78. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. 1992. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 9(12):1612-1616.
79. Murphy D, Rodriguez-Cintron F, Langevin B, Kelly RC, Rodriguez-Hornedo N. 2002. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int J Pharm 246(1-2):121-134.
80. Rodriguez-Hornedo N, Murphy D. 2004. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J Pharm Sci 93(2):449-460.
81. De Smidt JH, Fokkens JG, Grijseels H, Crommelin DJA. 1986. Dissolution of theophylline monohydrate and anhydrous theophylline in buffer solutions. J Pharm Sci 75(5):497-501.
82. Tsinman K, Avdeef A, Tsinman O, Voloboy D. 2009. Powder dissolution method for estimating rotating disk intrinsic dissolution rates of low solubility drugs. Pharm Res 26(9):2093-2100.
83. Jinno J, Oh D-M, Crison JR, Amidon GL. 2000. Dissolution of ionizable water-insoluble drugs: The combined effect of pH and surfactant. J Pharm Sci 89(2):268-274.
84. Maruyama S, Ooshima H. 2001. Mechanism of the solvent-mediated transformation of taltirelin polymorphs promoted by methanol. Chem Eng J (Lausanne) 81(1-3):1-7.
85. Gu C-H, Chatterjee K, Young V, Grant DJW. 2002. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. J Cryst Growth 235(1-4):471-481.
86. Gong Y, Collman BM, Mehrens SM, Lu E, Miller JM, Blackburn A, Grant DJW. 2008. Stable-form screening: Overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. J Pharm Sci 97(6):2130-2144.
87. Andronis V, Yoshioka M, Zografi G. 1997. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci 86(3):346-351.
88. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res 27(12):2704-2714.
89. Baird JA, van Eerdenbrugh B, Taylor LS. 2010. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci 99(9):3787-3806.
90. Fukuoka E, Makita M, Yamamura S. 1986. Some physicochemical properties of glassy indomethacin. Chem Pharm Bull 34(10):4314-4321.
91. Heinz A, Savolainen M, Rades T, Strachan CJ. 2007. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. Eur J Pharm Sci 32(3):182-192.
92. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14(12):1691-1698.
93. Taylor LS, Zografi G. 1998. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm Res 15(5):755-761.
94. Feth MP, Volz J, Hess U, Sturm E, Hummel R-P. 2008. Physicochemical, crystallographic, thermal, and spectroscopic behavior of crystalline and X-ray amorphous ciclesonide. J Pharm Sci 97(9):3765-3780.
95. Konno H, Handa T, Alonzo DE, Taylor LS. 2008. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70(2):493-499.
96. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5(6):981-993.
97. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
98. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
99. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231(2):131-144.
100. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12(23, 24):1068-1075.
101. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. 2002. Lonidamine solid dispersions: In vitro and in vivo evaluation. Drug Dev Ind Pharm 28(10):1241-1250.
102. Matteucci ME, Paguio JC, Miller MA, Williams RO, III, Johnston KP. 2009. Highly supersaturated solutions from dissolution of amorphous itraconazole microparticles at pH 6.8. Mol Pharm 6(2):375-385.
103. Sugimoto M, Okagaki T, Narisawa S, Koida Y, Nakajima K. 1998. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int J Pharm 160(1):11-19.
104. Wu K, Li J, Wang W, Winstead DA. 2009. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci 98(7):2422-2431.
105. Six K, Verreck G, Peeters J, Brewster M, van den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93(1):124-131.
106. van Eerdenbrugh B, van Speybroeck M, Mols R, Houthoofd K, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, van den Mooter G. 2009. Itraconazole/TPGS/Aerosil200 solid dispersions. Eur J Pharm Sci 38(3):270-278.
107. Allesoe M, Chieng N, Rehder S, Rantanen J, Rades T, Aaltonen J. 2009. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J Control Release 136(1):45-53.
108. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T, Takeichi YI, Azuma M, Houchi H, Minakuchi K. 2002. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci 91(2):362-370.
109. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. 2005. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm 293(1-2):155-164.
110. Bahl D, Bogner Robin H. 2008. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: The case of indomethacin. AAPS PharmSciTech 9(1):146-153.
111. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Crystal Growth Des 9(6):2950-2967.
112. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric Acids. J Am Chem Soc 126(41):13335-13342.
113. Lu J, Rohani S. 2009. Preparation and characterization of theophylline-nicotinamide cocrystal. Org Process Res Dev 13(6):1269-1275.
114. Rodriguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagan-Torres Y, Falkiewicz CJ. 2006. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm 3(3):362-367.
115. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res 25(11):2581-2592.
116. Huang N, Rodriguez-Hornedo N. 2010. Effect of micellar solubilization on cocrystal solubility and stability. Crystal Growth Des 10(5):2050-2053.
117. Shan N, Toda F, Jones W. 2002. Mechanochemistry and co-crystal formation: Effect of solvent on reaction kinetics. Chem Commun (Camb) 21(20):2372-2373.
118. Trask AV, Motherwell WDS, Jones W. 2004. Solvent-drop grinding: Green polymorph control of cocrystallisation. Chem Commun (Camb) 7(7):890-891.
119. Weyna DR, Shattock T, Vishweshwar P, Zaworotko MJ. 2009. Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: Mechanochemistry vs. slow evaporation from solution. Crystal Growth Des 9(2):1106-1123.
120. McHugh C, Erxleben A. 2011. Supramolecular structures and tautomerism of carboxylate salts of adenine and pharmaceutically relevant N6-substituted adenine. Crystal Growth Des 11:5096-5104.
121. Arenas-Garcia JI, Herrera-Ruiz D, Mondragon-Vasquez K, Morales-Rojas H, Hopfl H. 2011. Co-crystals of active pharmaceutical ingredients-Acetazolamide. Crystal Growth Des 10(8):3732-3742.
122. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. 2000. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 198(2):239-247.
123. Lin SL, Lachman L, Swartz CJ, Huebner CF. 1972. Preformulation investigation. I. Relation of salt forms and biological activity of an experimental antihypertensive. J Pharm Sci 61(9):1418-1422.
124. Psachoulias D, Vertzoni M, Goumas K, Kalioras V, Beato S, Butler J, Reppas C. 2011. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res 28:3145-3158.
125. Maeda T, Takenaka H, Yamahira Y, Noguchi T. 1980. Use of rabbits for absorption studies on polymorphs of chloramphenicol palmitate. Chem Pharm Bull 28(2):431-436.
126. Kim J-S, Kim M-S, Park HJ, Jin S-J, Lee S, Hwang S-J. 2008. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemicalcium using spray-drying and SAS process. Int J Pharm 359(1-2):211-219.
127. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R, Akrami A, Rose M, Surapaneni S, Bostick T, King A, Neervannan S, Ostovic D, Koparkar A. 2008. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 97(9):3942-3956.
128. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2010. Effects of crystal form on solubility and pharmacokinetics: A crystal engineering case study of lamotrigine. Crystal Growth Des 10(1):394-405.